Partial Epilepsies Clinical Trial
Official title:
A Multicenter, Open Label Study to Evaluate the Tolerability, Safety and Efficacy of Lacosamide (200mg - 400mg/Day) as add-on Therapy for Patients With Partial Onset Epilepsy Using a Flexible Dose-escalation Schedule and Individualized Maintenance Doses
To evaluate if a flexible dose escalation of lacosamide, up to the maximum approved dose of
400 mg/day, or to a clinically effective lower dose for an individual patient, improves the
tolerability and safety of lacosamide (200 mg to 400 mg/d) as add-on treatment for patients
with partial onset epilepsy.
Explanation of acronym: SELF = Safety Efficacy Lacosamide Flexibility
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00522275 -
Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
|
Phase 3 | |
| Completed |
NCT00955357 -
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
|
Phase 4 | |
| Completed |
NCT00552305 -
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
|
Phase 2 | |
| Completed |
NCT00655486 -
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
|
Phase 3 | |
| Completed |
NCT00655551 -
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
|
Phase 3 |